During the webinar, which took place earlier this month, senior officers and staff from the College explained the new guidance, what it will mean for the profession, and answered questions submitted by delegates.
The webinar was chaired by RCVS President Dr Melissa Donald MRCVS with a panel comprising Standards Committee Chair Linda Belton MRCVS, RCVS Registrar Eleanor Ferguson, and RCVS Head of Standards Gemma Kingswell.
The webinar included an overview of the main changes, the considerations to take into account when prescribing POM-Vs remotely, the circumstances under which POM-Vs cannot be prescribed remotely, the prescription of antibiotics, antifungals, antiparasitics and antivirals, and how the guidance will be enforced.
Eleanor Ferguson, RCVS Registrar, said: “We have also now published a range of practice-based scenarios to help explain how the new guidance should be followed in various circumstances, and in relation to different species.
"These scenarios cover a variety of different situations, including how the guidance applies to two or more practices with mutual clients, consultancy services and the prescription of long-term controlled drugs.”
A second webinar will be held on Monday 17th July, with priority for those who wanted to attend the June webinar but were not able to do because it was over-subscribed.
www.rcvs.org.uk/undercare
Elanco Animal Health has announced the launch of Kexxtone this month, a new treatment which it claims can reduce the incidence of ketosis in dairy cows by 74%* following a single treatment.1
Kexxtone is a targeted solution for any dairy cow or heifer that is expected to develop ketosis around the period of calving. It is administered as a bolus,and provides coverage during the main risk period for the condition.
Ketosis often goes undetected because the signs are not immediately apparent. However, it is a common condition, affecting around 30% of cows2 and has a negative impact upon cow health, fertility and milk production. Ketosis can result, on average, in milk losses of around 350-500 litres per cow4 per lactation. The cost of production losses and disease related consequential losses due to subclinical ketosis has been estimated at around 250-600 EUR per cow.5
Elanco says this new approach is likely to significantly expand the array of options open to vets actively involved in dairy herd health management. Kexxtone comes with the benefit of a zero day milk and meat withdrawal3 and the formulation is based on monensin - a molecule with a long history of beneficial use.
According to the company, Kexxtone uses novel technology to allow a continuous and regular release of the active ingredient into the rumen which forms a gel when exposed to rumen fluid. This gel is progressively released into the rumen by a pressure sensitive spring in the Kexxtone device. The active ingredient shifts the microbial balance in the rumen to produce more of the glucose precursor propionic acid, therefore increasing glucose delivery and ultimately increasing the energy available to the cow. This improvement in energy utilisation buffers dairy cows against the tendency to drop into negative energy balance during the transition period around calving and early lactation - the major cause of ketosis.
Mike Steele, Technical Consultant at Elanco said: "Kexxtone offers an exciting opportunity in which everyone wins - vets who can offer positive interventions able to make a big impact on the bottom line, are going to be increasingly integral to their farm clients' herd health planning framework. It's no longer just about nutritional intervention and emergency salvage; it's about being able to proactively easily measure the true herd prevalence of ketosis and where appropriate, take preventative targeted action to really make a difference."
Kexxtone is available to order now from veterinary wholesalers - for further information contact the Elanco Territory Manager or call Elanco Animal Health on 01256 353131.
References
BVA President Malcolm Morley said: “Judging this competition has been genuinely both extremely enjoyable and really difficult.
"The entries this year have absolutely surpassed expectations and the level of talent on display is amazing.
"However, the photographs we have chosen are all well worthy of being finalists.
"From photos that made us laugh out loud, to others that made some of us feel close to tears, they evoked a range of emotions, but we were also impressed by the quality of the images, the creativity of the photographers and the composition of the photos, as well as the stories behind the lens.
The finalists are:
Vets at work
All creatures great and small
Happy pets that make us smile
The winners will be announced at BVA Live at Birmingham’s NEC in May, where this year there is also an opportunity for BVA Live delegates to vote for their favourite image from the shortlist, with a new ‘People’s Choice’ winner being announced in the weeks following the event.
Felpreva contains emodepside and praziquantel, with tigolaner, a novel bispyrazole active ingredient.
Felpreva is licensed for treatment of cats with, or at risk from, mixed parasitic infestations/infections.
Vetoquinol points to a survey revealed conducted last year in which 43% of cat owners said that giving parasite protection to their cat makes them feel guilty, stressed, or worried1.
Felpreva provides an option to reduce the frequency of treatments, lessening stressful interactions between owners and their cats.
Vetoquinol says that with Felpreva’s convenience and longer-lasting flea and tick protection, it aims to help support compliance and thus improve the wellbeing of feline companions.
Helen Hunter, Senior Product Manager at Vetoquinol UK, said: “The launch of Felpreva is a truly proud moment for Vetoquinol, demonstrating our expertise, passion, and commitment to innovation in this essential category of companion animal medicine.
"It will allow us to safeguard the health of cats by bringing longer-lasting protection, convenience, and ease of use – for both pet owners and veterinary professionals.
"At a time when vets are treating more pets than ever before, the need for a breakthrough endectocide solution like Felpreva has never been greater.”
Felpreva is in wholesalers now.
For more information, contact your local Vetoquinol representative.
Reference
The group won the award in recognition of how it put social media at the heart of the its 80th birthday celebrations, offering employees 80 prizes over 80 days with daily draws broadcast on Facebook Live and uploaded to YouTube. The prizes included a weekend for two in New York, European holidays, festival tickets, a 40” smart TV, an extra week holiday, an Apple watch, a chance to be the MD for the day and more.
The IoIC’s judging panel praised the campaign’s recognition of staff, fun and innovation, as well as saying there was so much to love about the award entry and one even said it brought a lump to their throat.
Justin Phillips, head of marketing at White Cross Vets, said: "Celebrating our 80th birthday, with more than 200 team members spread across the North and Midlands, meant we had to come up with an accessible event, that would bond everyone and reinforce our reputation as the employer of choice within the veterinary industry.
"Broadcasting 80 prize draws in 80 days on Facebook Live ticked every box and was a fantastic spectacle that all our team members engaged with and talked about every day."
"The IoIC awards is one of the marketing industry’s most prestigious events, in a spectacular venue and surrounded by a wide range of global brands. These awards celebrate success, reward endeavour, inspire creativity and nurture best practice within the marketing community. For our campaign to have been recognised and rewarded by our peers is a huge source of pride within our business and has put a spring in the step of every single team member."
VetSurgeon Editor Arlo Guthrie said: "I've always admired the marketing and communications that comes from Justin and the rest of the team at White Cross. I think it's because as well as being fun, it's always sincere, something which is so often lacking in contemporary marketing communications. Anyway, with a little luck IVC will recognise the talent they've taken on, and sprinkle a bit of the White Cross magic across the rest of the group!"
Other category winners included household names like Oxfam, Volkswagen, Barclaycard, Sainsburys, Pets at Home, EDF Energy, Rolls Royce and Carlsberg.
The consultation, which was held by the College early in 2017, asked for the views of veterinary surgeons and nurses, animal owners, and stakeholders on the use of telemedicine in veterinary clinical practice.
The consultation was designed to help identify potential risks associated with telemedicine, identify areas where it may help address the needs of both clinicians and the public, and support the potential development of new professional standards and guidance.
The online survey of veterinary professionals received 1,230 responses, while the public consultation received 229 responses and the survey of organisations/stakeholders received eight responses.
The headline question asked of veterinary professionals was whether RCVS 'supporting guidance to the Code of Professional Conduct' should be amended to allow remote examination to take the place of physical examination in certain circumstances. 41% said 'Yes', 40% said 'No' and 18% were unsure.
Veterinary professionals and organisations were then asked a series of questions in order to establish how they rated the risk associated with telemedicine according to activity type, practice type, clinical sign or syndrome, mode of technology, and familiarity with client, animal or environment.
Unsurprisingly perhaps, the majority felt that providing just general advice presented a low risk. At the other end of the scale, most felt that the use of telemedicine to diagnose disease or injury would be either 'high risk', or 'not appropriate at all'.
Likewise, the majority said the risks would be low or medium where the client and environment were known and the animal seen before, for the same problem. By contrast, the majority said telemedicine would be either 'high risk' or 'not appropriate at all' when the client, animal and environment were all unknown.
When asked whether the current definition of 'under care' should be extended to allow veterinary surgeons to prescribe veterinary medicines where there has been no physical examination of the animal, 69% said 'No', 16% said 'Yes' and 15% were unsure.
However, when asked whether certain types of veterinary medicines should be able to be prescribed without a physical examination of the animal, the majority of respondents to the professional survey (52%) were in favour.
The results of the consultation were first considered at a special meeting of the Standards Committee in August 2017, where it was noted how the consultation had revealed significant confusion around current supporting guidance to the RCVS Code of Professional Conduct and that, at a minimum, clarification as to what was currently permissible was needed.
The Committee determined a key issue going forward was whether to change the Supporting Guidance to the RCVS Code of Professional Conduct regarding 'under care' to allow veterinary surgeons to prescribe POM-V medicines based on telemedicine alone.
Given the complex nature of the issues and the wide-ranging implications, the Standards Committee presented a range of options for amending RCVS Guidance to RCVS Council at its meeting in November 2017. After discussion, Council asked the Standards Committee to continue their review and to present more detailed proposals to Council regarding the future of telemedicine in clinical veterinary practice.
Anthony Roberts, RCVS Director of Leadership and Innovation, said: "We would like to thank all those who took the time to respond to the consultation – although Council has not yet made any firm decisions, we felt it would be useful to share our research so far.
"The use of telemedicine is growing rapidly in human healthcare and it is only right the RCVS assesses the opportunities it could bring to improve access to veterinary services. It is critical, however, that we understand the issues it presents 'at the coal face' and consider all the available evidence before making any changes to our Guidance. The RCVS should ensure its regulatory framework fosters innovation and maximises the opportunities to improve the quality, efficacy and accessibility of veterinary services, whilst at the same time protecting animal health and welfare."
The Standards Committee will meet again in April 2018 to take further evidence and develop proposals to take the issue forward.
Meanwhile, the full summary is available on the College’s website: www.rcvs.org.uk/telemeds-summary/.
Running in July, the campaign aims to raise awareness of hyperthyroidism in cats and hypothyroidism in dogs, educate pet owners to spot the symptoms and thereby encourage early diagnosis.
MSD Animal Health says it hopes the campaign will increase the number of pets being taken to their veterinary practice for diagnosis, and increase both return visits and treatment compliance.
Practices supporting Pet Thyroid Month will be supplied with resources to help them educate pet owners about the two conditions.
Caroline Darouj, product manager at MSD Animal Health, said: "Although hyperthyroidism in cats and hypothyroidism in dogs are well known conditions and diagnosis is generally straightforward, a large number of vets in Europe state that both disorders are under-diagnosed, due to the fact that pet owners don’t recognise the signs.
"We wanted to launch our Thyroid Month campaign to encourage pet owners to spot the early symptoms of thyroid issues in their pets and seek advice from their veterinary practices.
"Our aim is also to benefit and educate vets and vet nurses with regard to the use of Leventa and Vidalta in treating these manageable conditions in both dogs and cats."
To find out more about Pet Thyroid Month, visit www.vidalta.co.uk
The announcement came hot on the heels of announcements from Ceva and Boehringer that they too had vaccines in the pipeline.
Syvazul BTV3 is licensed to reduce viraemia, prevent mortality and reduce clinical signs and lesions in sheep and for the active immunisation against bluetongue virus serotype 3 in cattle.
Like all vaccines currently available for this serotype, the vaccine will not prevent infection and vaccinated animals will still be subject to bluetongue movement controls and trade restrictions currently in place.
Administered as a single 2ml dose subcutaneously in sheep and as two 4ml intramuscular doses 3 weeks apart in cattle, Syvazul BTV3 contains inactivated Bluetongue virus, serotype 3 (BTV-3), strain BTV-3/NET2023.
The vaccine is licenced for use during pregnancy and lactation in both sheep and cattle.
The onset of immunity is 28 days after the primary vaccine in sheep. A single booster revaccination dose of 2ml for sheep and 4ml for cattle is recommended after 12 months.
Presented in two pack sizes, 80ml and 200ml, Syvazul BTV3 vaccine has a shelf life of 2 years from manufacture and a broach life of 10 hours.
Licensing for use will be geographic, based upon high risk counties or by specific licence from the APHA.
According to a report in last weekend's Mail on Sunday, documents leaked from Defra have revealed proposals for a range of measures designed to reduce the risk from dangerous dogs.
The proposals reportedly include:
The first of these looks like being a bit of a non-runner. Aside from the subjective nature of deciding what makes a competent owner, the cost is disproportionate to the size of the problem: 703 convictions for dangerously out of control dogs in 2007. The other two seem long overdue.
Unite and the British Veterinary Union (BVU) have written to the government asking for the Professional Standards Authority (PSA), which regulates such governing bodies as the General Medical Council, General Dental Council, and Nursing and Midwifery Council (NMC), to have 'scrutiny' of the RCVS.
In a letter to junior minister at the Department for Environment, Food and Rural Affairs, George Eustice, the BVU chair Dr Shams Mir cited the case of Munhuwepasi Chikosi struck off the register of veterinary surgeons by the RCVS in June 2013.
Dr Mir said that this case was "widely seen by the veterinary profession as blatant miscarriage of justice and many expressions of 'outrage' were published in the veterinary press and online.
"One popular online veterinary forum recorded over a thousand posts criticising and challenging various aspects of the decision."
The current statutory duties of the RCVS, established by Royal Charter in 1844, are determined by the Veterinary Surgeons Act (VSA) of 1966, which Unite says is now 'outdated.
Dr Mir said: "BVU petitions the government to extend the remit of the PSA to incorporate the RCVS to ensure appropriate overview and scrutiny.
"The RCVS proposed new Royal Charter could be exploited by the RCVS to give itself proxy powers to introduce incontestable new regulatory measures."
Unite has asked for an urgent meeting with Mr. Eustice.
Unite professional officer Jane Beach said: "Our initiative is designed to safeguard the interests of both the public, and practicing vets and veterinary nurses in the UK.
"Basically, the way that the RCVS is presently constituted means that it is both judge and jury in disciplinary matters. It sets the rules and hands down the judgements - and we believe that an extra layer of scrutiny needs to be introduced which we would like to be the PSA."
Ceva Animal Health is launching Fiprospot, a new spot-on for dogs and cats.
Fiprospot contains fipronil, with its proven efficacy against fleas in dogs and cats and against ticks in dogs. The product is packaged in a novel dosing pipette which can be placed on its stand before gathering the dog or cat for their treatment. There are five pack sizes available for Fiprospot: one for cats and four for dogs, with either three or six pipettes per pack.
To find out more about Fiprospot and other products in Ceva's antiparasite range, telephone the customer support team on (01494) 781510 or contact your local Ceva territory manager.
Available for download now, the MobiVet Veterinary Formulary App is designed to make drug calculations and prescribing faster, easier and safer. It contains dose rate and interval data for over 250 drugs commonly used in small animal practice.
Searchable by drug name or trade names, with species-specific dosing information, the app calculates doses based on the patient type, weight, or body surface area as appropriate. MobiVet also provides a checklist of known relevant drug interactions for each medication, to prevent prescribing errors.
Stuart says an iOS version is in production.
To download the Android version, visit: https://play.google.com/store/apps/details?id=com.project.user.drug_formulary&hl=en
Lecture topics will include interesting cases, the importance of systematic abdominal technique, the challenge of becoming ultrasound competent within a primary referral setting, basic anaesthetic nerve blocks, using ultrasound for appropriate medical management, how CASE can support competency based veterinary ultrasound training and more.
The session will end with a debate on whether it is time for a formal / stand alone Veterinary Ultrasound training programme and who should accredit such courses.
Speakers include Natasha Dickinson from Cave Veterinary Specialists, Niamh Casey from Village Vets, Miguel Martinez from Northwest Veterinary Specialists, Will Humphreys from the University of Liverpool and Nuala Summerfield from Virtual Veterinary Specialists.
The day costs £75 (sounds like a steal, if you ask me), and you can register here: https://www.bmus.org/meeting-booking/ultrasound-2019/
Fourteen veterinary surgeons stood for election this year and 8,542 voted, a turnout of 24.5% of eligible voters. That compares with a turnout of 26.2% in 2020, 25.5% in 2019 and 22.7% in 2018.
Danny scored a total of 4,759 votes, leaving the other successful candidates Tshidi Gardiner, Colin Whiting and Louise Allum nevertheless trailing in his wake, with 3,228 votes, 2,957 votes and 2,368 votes respectively.
The VN Council election also had fourteen candidates standing for one elected place, the other having been taken by Susan Howarth RVN who was automatically re-elected as the only candidate standing at the time of the original deadline in January.
Donna Lewis was elected with 404 votes from those cast by 2,341 veterinary nurses, which amounted to a turnout of 12.4% of eligible voters. That compares with a turnout of 17.1% in 2020, 14.5% in 2017 and 10.9% in 2016.
All of those elected to either RCVS or VN Councils will formally take up their seats at the RCVS Annual General Meeting on Friday 9 July 2021.
Eleanor Ferguson, RCVS Registrar and Returning Officer for both elections, said: “Thank you to all those who stood as candidates and all those who voted in this year’s elections, especially in view of all the extra demands on everyone’s time at the moment. Many congratulations to our five successful candidates with whom we look forward to working over the coming months and years.
“Even though the elections were held during the ongoing pandemic, the RCVS Council election still produced the third highest turnout on record, and turnout in both elections was above the average for those held over the last ten years.
“As always, we made concerted efforts to let people know about this year’s election, which included additional reminder emails sent on behalf of the RCVS by our election provider Civica Election Services, as well as regular email reminders and social media posts from the RCVS. We do, of course, always endeavour to improve turnout, and will continue to review this going forward.”
Photo: Left to right, Danny Chambers, Tshidi Gardiner, Colin Whiting and Louise Allum.
Trilotab is licensed for the treatment of pituitary-dependent hypercortisolism (PDH) caused by an adrenocorticotrophic hormone (ACTH)-secreting pituitary adenoma, which accounts for 85% of spontaneous cases of Cushing’s, and for the treatment of adreno-dependent hyperadrenocorticism (ADH) caused by a cortisol-secreting adrenocortical tumour (ACT), which accounts for the remaining 15% of spontaneous cases1.
The new tablet is divisible into halves and quarters to facilitate dose adjustment and make administration easier.
Divided tablets remain stable outside of the blister packaging until the next dose is due, thereby avoiding wastage.
Trilotab tablets are chewable and chicken-flavoured to help improve treatment compliance.
They contain hydrolysed chicken flavouring so they can be prescribed for pets allergic to chicken.
Trilotab is administered once daily with food with a starting dose of 2mg trilostane/kg bodyweight.
The new tabs are available in three presentations: 10mg, 30mg, and 60mg presentations, which Virbac says should help practices reduce their dispensary stockholding.
Andrew Connolly, Marketing Director – UK & Ireland at Virbac, said: ‘The complex nature of Cushing’s syndrome in dogs can make it a challenging condition to manage for both the clinician and the pet owner.
"With the requirement for lifelong treatment, it is our hope that Trilotab’s easy administration and simplified dosing protocols will genuinely help to improve the lives of dogs affected by the disease, whilst making the clinician and pet owner’s lives just a little bit easier too!"
Norbrook has announced the re-launch of its range of intramammary tubes for lactating and dry cows, to promote holistic herd health and responsible use of antimicrobials.
The company’s range, which includes products across a number of antibiotic classes, primarily targets clinical cases of mastitis in lactating cows, and removal or prevention of infection around the dry period.
Chris Geddes MRCVS, Marketing Manager at Norbrook, says the re-launch is focused on modernising the range and making it clearer for practice staff and farmers to avoid confusion between lactating cow and dry cow products: “We have a wide range of 11 products containing a variety of antimicrobials: for example Duofast is the only lactating cow product to contain trimethoprim and sulfadiazine. We are working with vets to promote responsible use by farmers, for example through the use of our teat sealant Noroseal for Selective Dry Cow Therapy."
The full range includes Duofast, Lactaclox, Cefimam LC, Combiclav, Noroclav and Multiject for the lactating cow; Cefimam DC, Noroclox, Bovaclox and Bovaclox DC Xtra for the dry cow; and teat sealant Noroseal.
Norbrook has also produced a best practice guide to mastitis control, available for vets in English and Polish, which can be shared with farmers.
Chris added: "We recognise the need to reduce overall use of antimicrobials, especially for disease prevention – as well as using non-antimicrobial products such as teat sealants. These practices, together with the recent focus on using older classes of antimicrobials, mean that as an industry we need to adopt a holistic and targeted approach to herd health management.
"We believe that by providing additional information to aid with prevention of disease, and re-launching our intramammary range to make it clearer when products should be used, we can help to achieve that."
Norbrook says the full range of products is in stock, but some wholesalers may hold components of the old range as the new range is phased in.
Elle says she created the course she wished she had when she first qualified, one which offers provides practical tools and tailored support to build confidence, overcome self-doubt, and thrive in veterinary practice.
She said: “I remember what it felt like to step into practice as a newly qualified vet nurse—feeling unsure, overwhelmed, and constantly questioning whether I was good enough.
"That’s why I created this course - to give vet professionals the support and confidence they deserve.”
The Confidence Coaching CPD Course includes:
Elle says the course is ideal for both vets and vet nurses, in particular those struggling with confidence in their clinical skills, and professionals looking to progress in their careers.
The course costs £350, but as part of the launch, Elle is offering a 25% limited-time discount for those who sign up early using the code: PVN25.
https://thepositivevetnurse.com/cpd-course
The Queen’s Medal - the highest honour that the RCVS can bestow upon an individual veterinary surgeon - was given to Dr Mary Stewart MRCVS, a retired academic who spent most of her career at the University of Glasgow where she was responsible for the development of the modern vet school.
Dr Stewart was nominated by Professor Stuart Reid, the Principal of the Royal Veterinary College and former Dean of the Glasgow Veterinary School. In his nomination he said: “Mary Stewart is one of the unsung heroes of the veterinary profession. A veterinarian graduating from Cornell in 1949, Mary has been MRCVS since 1951 and without doubt has been one of the major influencers of ethical approaches in the vet-client-patient environment and, in particular, the impact of euthanasia on both owners and attending veterinarians. Conducting nearly all her professional career in the UK, the vast majority at the University of Glasgow, Mary was of the generation selected by Sir William Weipers to create the modern school at Glasgow, an institution in which Mary played a pivotal role that would have reach nationally and internationally.”
The Inspiration Award is given to vets or nurses to recognise their ability to inspire and enthuse others consistently throughout his or her career. This year, it has been awarded to Dr Freda Scott-Park MRCVS. Freda is a former president of both the British Veterinary Association (BVA) and the British Small Animal Veterinary Association (BSAVA) as well as the current coordinator of the Highlands & Islands Veterinary Services Scheme and a campaigner for identifying the links between animal and other forms of abuse through The Links Group.
The Impact Award is given to vets and nurses who have recently made a considerable impact that has affected the profession at large, animal health or welfare, or public health. This year two Impact Awards have been bestowed. The first is to Dr Rosie Allister MRCVS, a leading campaigner and researcher for and about veterinary mental health, as well as a veterinary educator, the manager of the Vetlife Helpline and a member of the RCVS Mind Matters Initiative Taskforce.
The second Impact Award recipient is Hannah Capon MRCVS, the co-founder and director of Canine Arthritis Management (CAM), a self-funded social enterprise that provides advice to both other veterinary professionals and animal owners on the treatment and management of arthritis in dogs.
This year the RCVS is also awarding three Honorary Associateships, bestowed upon those who are not veterinary surgeons or veterinary nurses but who are making a considerable impact in the veterinary sphere, whether in the field of campaigning, charities, research, politics or journalism, for example.
This year’s first Honorary Associate is Professor Maureen Bain, Professor of Comparative Anatomy and Histology at the University of Glasgow’s Institute of Biodiversity, Animal Health & Comparative Medicine, and an Associate of Glasgow Vet School who has dedicated her career to research on improving the quality and safety of eggs for human consumption.
The second Honorary Associate is Mike Flynn, the Chief Superintended of the Scottish Society for the Prevention of Cruelty to Animals (SSPCA), for his collaborative work with the veterinary profession in areas such as the illegal puppy trade and the Links Group.
The third and final Honorary Associate is Professor Roberto La Ragione, the Deputy Head of the Surrey Vet School where he is also Professor of Veterinary Microbiology and Pathology and Head of the Department of Pathology and Infectious Diseases. Professor La Ragione was nominated for his contribution to veterinary education and research.
RCVS President Niall Connell (pictured right) said: “My hearty congratulations to all of this year’s award winners. Once again, it was a very strong field of people who have made and are making an indelible impact on veterinary science, the professions, animal health and welfare, food safety, public health, and plenty more besides."
Normally RCVS Awards & Honours are presented at Royal College Day in July. However, due to the coronavirus pandemic, the 2020 awards ceremony will instead be part of the proceedings of a combined Royal College Day and Fellowship Day, which will take at the Royal Institution on 2 October 2020. This event may be subject to cancellation and postponement depending on the latest Government advice and restrictions on the prevention of transmission of coronavirus.
Vets for Ukrainian Pets will cover the treatment costs of up to five dogs, cats, horses or other pet animals, up to 250 Euros per animal, for acute care and medication, rabies and other vaccinations as well as microchipping and medical examination required for safe passage through the EU.
The initiative is being funded by HSI, with support from Mars.
It is being run collaboration with Federation of Veterinarians in Europe and the Federation of European Companion Animal Veterinary Associations.
Reimbursements for participating veterinary surgeons will be available wherever the FECAVA has members, including in the United Kingdom, Germany, Italy, Romania and Poland, as well as Ukraine.
Ruud Tombrock, executive director of HSI/Europe, said: “In Europe’s biggest refugee crisis since WWII, millions of Ukrainians have had to take the decision to leave their country and flee the war.
"Along with a few possessions, many are also taking their pet animals, who they cherish as family members.
"The trauma of war as well as the stress of the evacuation journey, can make animals vulnerable to a variety of illnesses and so HSI’s Vets for Ukrainian Pets program aims to eliminate barriers to accessing veterinary care for the pets of refugees.
"It will provide a much-needed safety net for those families fleeing with their beloved pets so that at no point they feel compelled to leave their pets behind due to concerns about being able to care for them.”
Vets for Ukrainian Pets will run until 21st May 2022 and is open for all licensed veterinary clinics to apply throughout Europe, whether owned privately or as part of a corporate group.
Veterinary surgeons who want to join the program should visit apply.vetsforukraine.com.
Historically, diagnosis has been achieved with multiple blood tests. However, this process can be time-consuming, expensive and in some cases does not provide accurate results.
In an attempt to address these diagnostic challenges, the researchers, with funding from Dechra, assessed anonymised data from 939 dogs which had been tested for Cushing’s syndrome from the VetCompass population of 905,554 dogs and 886 veterinary practices across the UK1.
Using structured clinical data to look at the dogs’ demographics, clinical signs at presentation and laboratory results, machine-learning algorithms were applied to predict a future diagnosis of Cushing’s syndrome. Dogs suspected of having Cushing’s syndrome were included in the analysis and classified based on their final reported diagnosis within their clinical records.
The researchers say that the findings indicate that machine-learning aided diagnosis could predict the diagnosis of a practising veterinary surgeon and that using machine-learning methods in clinical practice could contribute to improved diagnosis of Cushing’s syndrome in dogs.
Additionally, further development of these algorithms could lead to earlier, more reliable and cost-effective diagnoses and therefore, better clinical care for dogs with Cushing’s syndrome. This could also create opportunities for this technology to be applied to other clinical problems.
Imogen Schofield, lead author and PhD student at the RVC, said: “Machine-learning algorithms, like those used in this study, are already widely integrated in our day-to-day lives to help make certain decisions, such as Google or Netflix recommendations. Now this technology can be harnessed to help improve diagnostics in veterinary practice.
"By embracing the use of machine-learning methods, we are a step closer to providing vets in primary-care practice with an easy to use, low cost and accurate test that can support the often frustrating process of diagnosing Cushing’s syndrome in dogs."
Greg Williams, Senior Business Manager at Dechra Ltd. and Industrial Supervisor of the PhD studentship, said: “By funding Imogen's PhD and working with the RVC we have been able to develop validated clinical scoring and quality-of-life assessments to help vets deliver effective control and management of Cushing's syndrome in dogs.
Redonyl Ultra contains essential fatty acids, Palmitoylethanolamide (PEA) and Biotin.
PEA is a naturally-occurring bio modulator which Dechra says has scientifically proven activity against the mechanisms that contribute to inflammation and pain, while Biotin is important for synthesis of fatty acids and support of optimal skin condition.
Dechra Brand Manager Claire Morgan said: "Redonyl Ultra is a great addition to Dechra’s extensive Dermatology range that allows an holistic approach to treatment, control and maintenance of dermatological conditions.
"Allergic skin conditions are among the most common causes of skin and ear disease in cats and dogs, and it is estimated that up to 15 per cent of dogs are affected by atopy. In situations where an allergen cannot be avoided, multi-modal therapy is useful to control the clinical signs."
Redonyl Ultra comes in a convenient bottle size of 60 skittle capsules, in two strengths for different sized animals. The capsules can be opened and given with food or ingested directly, or swallowed whole for flexible administration.
For more information, visit http://bit.ly/2iNa2Ik
The British Veterinary Association (BVA) has launched its new ‘Good Practice Guide to Handling Veterinary Waste’ consisting of a poster and web advice.
Produced in association with the BSAVA and Goat Veterinary Society, and supported by The Environment Agency, the poster, alongside further detailed information on the BVA website, provides practical step-by-step guidance designed to assist veterinary surgeons comply with waste regulations in England and Wales.
BVA President Nick Blayney commended the guide to practices, pointing out that “All businesses have a duty of care to ensure that all waste is stored and disposed of responsibly, that it is only handled or dealt with by those authorised to do so and that appropriate records are kept of all waste that is transferred or received. Under the Hazardous Waste Regulations, all veterinary facilities that produce more than 200 kg of hazardous waste per annum need to register and we realised that this was an area where guidance was needed.”
While the production of the guidance had proved to be “a decidedly complicated and time-consuming exercise, we are” said Mr Blayney “absolutely delighted with the outcome and believe that it will make life considerably easier for the profession.”
With definitions of hazardous, including clinical, waste and non-hazardous waste illustrated simply and clearly, coupled with information on registering of premises, maintaining a waste register and the use of consignment notes the BVA is confident that the guide will prove indispensable.
The company says the reason for the change is so that it can dedicate additional resources to the business.
Samantha Williamson, UK Country Manager at Animalcare, said: "Through our identichip microchips and our identibase pet database, we provide one of the UK’s longest-established pet microchipping services and are helping to reunite owners with their lost pets every single day.
"The pet reunification sector is evolving rapidly thanks to technological advances. We believe that the creation of identicare will facilitate the concentration of resources and expert knowledge needed to fuel the growth in our identichip business and continued enhancements to the identibase pet database. identicare will share the same passion and values as Animalcare and there will be no outward change for our customers.
“We look forward to continuing to deliver our ambition of delivering the highest quality pet reunification service under the identicare banner.”
The new company is part of the Animalcare Group.
The new technique enables the surgeon to suspend a modified acrylic lens from a damaged capsule, which has historically not been possible.
Gary and Chris have published a paper analysing the results of the surgery in the Journal of Small Animal Practice: "Post-operative outcomes in canine eyes receiving a rhexis-fixated prosthetic intra-ocular lens: 30 cases (2014-2020)1"
Surgery was carried out in a total of 30 eyes using a modified acrylic IOL, where the lens capsule could not accommodate a conventional prosthetic endo-capsular IOL.
Over a follow-up period from three to 76 months, 26 of the 30 eyes remained visual.
Chris said: “It’s a novel technique for implanting a prosthetic lens into the eyes of patients who otherwise may have not been suitable for surgery, either saving or restoring their sight.
“Gary developed a method of modifying the lens to fit in the eye in dogs where the lens capsule is damaged.
For more information, visit www.veterinaryvision.co.uk.
Animalcare's new Cephacare flavour antibiotic has received a response of 'good' or 'very good' in 80% of cases in a recent field study of superficial pyoderma in dogs. When asked to rate the effectiveness of the cephalexin-based antibiotic, more than half of the cases were awarded the highest response level of 'very good'.
Animalcare asked vets from across the country to participate in the study in order to confirm the company's own opinion. Each vet recorded five cases of superficial pyoderma in dogs and scored the effectiveness of treating the condition with Cephacare flavour. The first vets to complete their assessment forms received a free copy of the BSAVA Manual of Small Animal Dermatology worth £85.
The antibiotic proved effective across 19 different breeds, with animal weights ranging from 7kg to 70kg. Varying degrees of condition severity from mild through to severe were recorded with the average treatment length being 14-17 days. A number of 'severe' cases were treated with positive results. Severe was defined as long standing or recurrent areas of papules, crusting papules, epidermal collarettes and intact pustules.
Tony Liepman, Animalcare Market Manager, said: "A study like this confirms the product's effectiveness and, importantly, the acceptance of Cephacare flavour in real-world cases."